Global Nuclear Medicine Market Growth (Status and Outlook) 2023-2029

Global Nuclear Medicine Market Growth (Status and Outlook) 2023-2029

Nuclear Medicine，or Radiopharmaceuticals， are radioactive compounds administered to the patient, and monitored via specific imaging devices, for diagnosis and therapeutic purposes. It is composed of a radioisotope bond to an organic molecule. The organic molecule conveys the radioisotope to specific organs, tissues or cells. The radioisotope is selected for its properties. Radiopharmaceuticals are used in the field of nuclear medicine as radioactive tracers in medical imaging and in therapy for many diseases (for example, brachytherapy). Many radiopharmaceuticals use technetium-99m (Tc-99m) which has many useful properties as a gamma-emitting tracer nuclide.

LPI (LP Information)' newest research report, the “Nuclear Medicine Industry Forecast” looks at past sales and reviews total world Nuclear Medicine sales in 2022, providing a comprehensive analysis by region and market sector of projected Nuclear Medicine sales for 2023 through 2029. With Nuclear Medicine sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Nuclear Medicine industry.

This Insight Report provides a comprehensive analysis of the global Nuclear Medicine landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Nuclear Medicine portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Nuclear Medicine market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Nuclear Medicine and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Nuclear Medicine.

The global Nuclear Medicine market size is projected to grow from US$ 6054.6 million in 2022 to US$ 10160 million in 2029; it is expected to grow at a CAGR of 7.7% from 2023 to 2029.

North America is the largest consumption area, with a consumption market share nearly 50%. Following North America, Europe is the second place consumption region with the consumption market share of about 25%.

Global Nuclear Medicine key manufacturers include GE Healthcare, Bracco Imaging, etc. The global top 2 manufacturers account for over 30 percent of total share.

The classification of Nuclear Medicine includes Tc-99, I-123/131, In-111, Xe-133, Th-201 and Ga-67, and the proportion of Tc-99 is about 50%.

Nuclear Medicine is widely used in Diagnostic, Therapeutic. The most proportion of Nuclear Medicine is Diagnostic, and the market share is over 60%.

This report presents a comprehensive overview, market shares, and growth opportunities of Nuclear Medicine market by product type, application, key players and key regions and countries.

Market Segmentation:

Segmentation by type

Tc-99

I-123/131

In-111

Xe-133

Th-201

Ga-67

Others

Segmentation by application

Diagnostic

Therapeutic

This report also splits the market by region:

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.

GE Healthcare

Bracco Imaging

Mallinckrodt

Lantheus Medical Imaging

Bayer

Triad Isotopes

Nordion

Jubilant Pharma

Eli Lilly

SIEMENS

China Isotope & Radiation

Dongcheng

Please note: The report will take approximately 2 business days to prepare and deliver.